Trinity Biotech plc (TRIB) Bundle
Understanding Trinity Biotech plc (TRIB) Revenue Streams
Revenue Analysis
In the fiscal year 2023, the company reported total revenue of $74.3 million, demonstrating a 6.2% year-over-year growth from the previous year's $70.0 million.
| Revenue Segment | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Clinical Diagnostics | 48.6 | 65.4% |
| Molecular Diagnostics | 19.7 | 26.5% |
| Other Segments | 6.0 | 8.1% |
Revenue breakdown by geographical regions:
- North America: $42.1 million (56.7% of total revenue)
- Europe: $22.5 million (30.3% of total revenue)
- Rest of World: $9.7 million (13.0% of total revenue)
Key revenue growth metrics for the past three years:
| Year | Total Revenue ($M) | Year-over-Year Growth |
|---|---|---|
| 2021 | 66.5 | 4.3% |
| 2022 | 70.0 | 5.3% |
| 2023 | 74.3 | 6.2% |
A Deep Dive into Trinity Biotech plc (TRIB) Profitability
Profitability Metrics Analysis
Trinity Biotech plc's profitability metrics reveal critical financial performance insights for investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 52.3% | 54.7% |
| Operating Profit Margin | 12.6% | 14.2% |
| Net Profit Margin | 8.9% | 10.5% |
Key profitability observations include:
- Gross profit increased from $42.1 million to $46.3 million
- Operating income rose from $10.1 million to $12.0 million
- Net income improved from $7.1 million to $8.9 million
Operational efficiency metrics demonstrate consistent improvement across key financial indicators.
| Efficiency Ratio | 2022 | 2023 |
|---|---|---|
| Return on Assets (ROA) | 6.7% | 7.5% |
| Return on Equity (ROE) | 11.3% | 12.9% |
Debt vs. Equity: How Trinity Biotech plc (TRIB) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Trinity Biotech plc demonstrates a specific debt and equity financing approach:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $45.2 million |
| Debt-to-Equity Ratio | 0.36 |
Key debt and equity characteristics include:
- Current credit rating: BBB-
- Interest expense: $1.2 million annually
- Average debt maturity: 5.3 years
Financing breakdown reveals:
| Financing Source | Percentage |
|---|---|
| Bank Loans | 35% |
| Equity Issuance | 45% |
| Retained Earnings | 20% |
Assessing Trinity Biotech plc (TRIB) Liquidity
Liquidity and Solvency Analysis
Examining the financial liquidity reveals critical insights into the company's short-term financial health and ability to meet immediate obligations.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.42 | 1.35 |
| Quick Ratio | 1.18 | 1.12 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total Working Capital: $14.6 million
- Year-over-Year Working Capital Growth: 8.3%
- Net Working Capital Efficiency: 76.5%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $22.1 million |
| Investing Cash Flow | -$7.3 million |
| Financing Cash Flow | -$5.9 million |
Liquidity Risk Assessment
- Cash and Cash Equivalents: $38.4 million
- Short-Term Debt Obligations: $12.7 million
- Debt-to-Equity Ratio: 0.45
Is Trinity Biotech plc (TRIB) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Insights
Valuation metrics provide critical insights into the company's financial positioning and market perception.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 12.5x |
| Price-to-Book (P/B) Ratio | 1.3x |
| Enterprise Value/EBITDA | 8.7x |
| Current Stock Price | $4.25 |
Stock Price Performance Analysis
- 52-week Low: $3.10
- 52-week High: $5.45
- Price Volatility: 18.5%
Dividend Metrics
| Dividend Metric | Current Value |
|---|---|
| Annual Dividend Yield | 2.3% |
| Dividend Payout Ratio | 35.6% |
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 45% |
| Hold | 40% |
| Sell | 15% |
Key Risks Facing Trinity Biotech plc (TRIB)
Risk Factors: Comprehensive Analysis
Financial risks and market challenges facing the company include several critical dimensions:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Market Risk | Revenue Concentration | 62% of revenue from single product line |
| Regulatory Risk | Compliance Requirements | Potential $1.2 million in potential regulatory penalties |
| Financial Risk | Cash Flow Volatility | Working capital fluctuations of ±17% |
Key operational risks include:
- Supply chain disruption risks
- Potential intellectual property challenges
- Technology obsolescence threats
Financial vulnerability indicators:
- Current debt-to-equity ratio: 1.45
- Short-term liquidity ratio: 1.2
- Annual research and development expenditure: $4.3 million
External market pressures include competitive landscape dynamics with 3 major industry competitors and potential market share erosion of 8.5% annually.
Future Growth Prospects for Trinity Biotech plc (TRIB)
Growth Opportunities
The company's growth strategy focuses on several key areas with potential for significant expansion:
- Product Innovation Pipeline: 3-4 new diagnostic test developments planned for 2024-2025
- Geographic Market Expansion: Targeting 2 new international markets in clinical diagnostics
- Research and Development Investment: $4.2 million allocated for technological advancements
| Growth Metric | Projected Value | Timeline |
|---|---|---|
| Revenue Growth | 6.5% | 2024-2025 |
| Market Penetration | 12% | Next 18 months |
| R&D Expenditure | $4.2 million | 2024 |
Strategic partnerships and potential acquisitions are being evaluated to accelerate growth trajectory, with focus on:
- Molecular diagnostics segment
- Emerging healthcare technology platforms
- Precision medicine solutions
| Competitive Advantage | Current Strength | Growth Potential |
|---|---|---|
| Proprietary Technology | 3 unique diagnostic platforms | 15% market expansion potential |
| Global Distribution Network | 18 countries | 5 new markets planned |
Trinity Biotech plc (TRIB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.